Pipeline

Through the application of BiMM technology, InnoTherapy has succeeded in developing a biocompatible hemostatic pad with outstanding hemostatic capabilities. By expanding the application of BiMM technology to biopharmaceuticals, our research has led to the creation of products that break through the limitations of conventional pharmaceutical development of medical sealants.

Research

Non-clinical

Clinical

Approval

Bleeding

InnoSEAL

On-market   

Approval status

KR (2015, on market)

USA (2016), Japan (2018), Hongkong (2019), Pakistan (2019), Israel (2020), Argentina (2020), Malaysia (2020)

Description

InnoSEAL is mainly used in Interventional Radiology and Cardiology for hemostasis of the radial artery or femoral artery access site following non-invasive catheterization procedures. InnoSEAL has been launched in number of international markets including USA and Japan.

InnoSEAL PLUS

  • Approval status
  • KR (2019)

Description

InnoSEAL Plus is the very first absorbable hemostatic product incorporating InnoTherapy’s technology. The Korean Ministry of Food and Drug Safety (KMFDS) approved InnoSEAL Plus as a Class IV Medical Device in October 2019.

EndoSil

  • Approval status
  • KR (2019)

Description

EndoSil is an absorbable hemostatic agent used to control gastrointestinal bleeding that may occur during endoscopic surgery. The unique properties of EndoSil enable it to be used as hemostatic agent in areas of the digestive tract that have traditionally posed difficulties because of the nature of mucosal tissues and the secretion of gastric acid.

GellySil

Description

GellySil combines a widely used biomaterial with a proprietary material developed by InnoTherapy to produce an easy-to-use hemostatic agent with a variety of applications. GellySil is anticipated to serve as a versatile product with applications in diverse surgical environments such as laparscopic and endoscopic procedures.

Leakage

Film
product

Description

Film-type surgical sealant is used for the complete sealing of anastomosis sites. The tensile strength of the biomaterial combined with the adhesive ability of InnoTherapy’s proprietary material enables sealing of vascular or gastrointestinal anastomosis sites without disturbing blood flow or peristalsis.

STOP
needle

Description

The STOP Needle is coated with a proprietary hemostatic agent that can fundamentally block potential hemorrhaging or infections from the puncture site of vascular injections. The STOP Needle is expected to make a significant contribution to controlling and lowering the incidence of hospital-acquired infections to both patients and medical staff.

STOP
needle
(ophthalmic)

Description

This version of the STOP Needle has been optimized for use in ophthalmology. The STOP Needle prevents potential leakage of drugs injected into the intraocular space thereby maintaining the intended level of the drug and improving therapeutic efficacy. Among common eye disorders, macular degeneration is a condition for which a large number of companies are developing therapeutic agents; however, drugs that are currently on the market or those under development are all extremely costly. The use of the intraocular STOP Needle is thus expected to reduce the cost of such therapies by allow for a more efficient, targeted application of these drugs.

Wound

Wound
dressing patch

Description

Wound dressing patch is being developed via research on novel and unconventional materials. It can be applied to various wounds (chronic wounds, burns, etc.) for the purpose of absorbing would exudate, preventing hemorrhage or loss of body fluid, protecting the wound area, and facilitating healing.

Biomedicine

Gene therapy
(target delivery)

Description

One of the critical challenges of gene therapy is the development of techniques that enable gene therapies to be delivered to the target organ via intravenous injection. Our patented materials can bind to a variety of proteins and be organ-specifically distributed after being systemically injected into the body. Our aim is to leverage the unique features of our proprietary materials to develop a universal delivery platform for gene therapy. We are especially focused on the use of adeno-associated viruses (AAV) as an emerging and promising delivery mechanism for gene therapies.